A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors



Status:Completed
Conditions:Breast Cancer, Lung Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/5/2019
Start Date:March 2015
End Date:August 2017

Use our guide to learn which trials are right for you!

A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors

This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid
tumors.


Inclusion Criteria:

1. Pathologically confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or
squamous-cell carcinoma), Breast Cancer (HER2 positive or triple negative), Pancreatic
Cancer (adenocarcinoma)

2. Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have
failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior
treatments.

3. Measurable lesion by RECIST 1.1

4. Adequate hematologic function:

- ANC >1500 cells/mm3

- Platelet count >100,000 cells/mm3

- HGB >9.0 g/dL

5. Adequate hepatic and renal function:

- AST and ALT ≤2.5 x ULN for subjects without liver metastases and ≤3.5 x ULN for
subjects with liver metastases

- Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
non-hepatic origin)

- Creatinine ≤2.0 x ULN and Creatinine Clearance ≥40 mL/min (Cockcroft-Gault or
24-hour creatinine clearance collection)

6. PT/INR <1.5 x ULN and PTT/ aPTT <1.5 x ULN

Exclusion Criteria:

1. Mixed small cell and NSCLC histology

2. A history of CNS involvement except as follows: Subjects with previously treated CNS
metastases that are adequately treated with whole brain radiotherapy, that are
neurologically stable, and do not require corticosteroids for symptomatic management
for at least 14 days prior to first dose of study drug. There must be no clear
evidence of radiographically active disease for at least 90 days prior to enrollment.

3. Anti-tumor therapy within 21 days of study Day 1

4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.
The following are exceptions to this criterion: Subjects previously treated with an
anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.

5. History of allogeneic organ transplant

6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
We found this trial at
18
sites
Chicago, Illinois
Phone: 408-990-7366
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Birmingham, Alabama
Phone: 408-990-7366
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Durham, North Carolina
Phone: 408-990-7736
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gainesville, Florida 32610
Phone: 408-990-7366
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Hackensack, New Jersey 07601
Phone: 408-990-7366
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Houston, Texas
Phone: 408-990-7366
?
mi
from
Houston, TX
Click here to add this to my saved trials
La Jolla, California 92093
Phone: 408-990-7366
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California
Phone: 408-990-7366
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37232
Phone: 408-990-7366
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Orlando, Florida 32804
Phone: 408-990-7366
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Palo Alto, California 94301
Phone: 408-990-7366
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Peoria, Illinois 61603
Phone: 408-990-7366
?
mi
from
Peoria, IL
Click here to add this to my saved trials
San Antonio, Texas 78224
Phone: 408-990-7366
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Francisco, California
Phone: 408-990-7366
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Scottsdale, Arizona
Phone: 408-990-7366
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials